MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Regeneron Pharmaceuticals Inc

Deschisă

SectorSănătate

595.35 0.18

Rezumat

Modificarea prețului

24h

Curent

Minim

583.66

Maxim

599.49

Indicatori cheie

By Trading Economics

Venit

-423M

918M

Vânzări

69M

3.8B

P/E

Medie Sector

14.641

57.333

EPS

12.07

Randament dividend

0.63

Marjă de profit

24.219

Angajați

15,106

EBITDA

-534M

1.1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+47.02% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.63%

2.63%

Următoarele câștiguri

29 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-13B

62B

Deschiderea anterioară

595.17

Închiderea anterioară

595.35

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Regeneron Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 feb. 2025, 12:13 UTC

Câștiguri

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

22 apr. 2025, 10:51 UTC

Top știri

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb. 2025, 11:58 UTC

Câștiguri

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb. 2025, 11:37 UTC

Câștiguri

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb. 2025, 11:37 UTC

Câștiguri

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb. 2025, 11:36 UTC

Câștiguri

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb. 2025, 11:35 UTC

Câștiguri

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb. 2025, 11:35 UTC

Câștiguri

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb. 2025, 11:34 UTC

Câștiguri

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb. 2025, 11:34 UTC

Câștiguri

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 feb. 2025, 11:32 UTC

Câștiguri

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 feb. 2025, 11:31 UTC

Câștiguri

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 ian. 2025, 08:30 UTC

Achiziții, Fuziuni, Preluări

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 oct. 2024, 13:58 UTC

Câștiguri

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 oct. 2024, 10:52 UTC

Câștiguri

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 oct. 2024, 10:34 UTC

Câștiguri

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 oct. 2024, 10:33 UTC

Câștiguri

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 oct. 2024, 10:33 UTC

Câștiguri

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 oct. 2024, 10:32 UTC

Câștiguri

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 oct. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 3Q Rev $3.72B >REGN

31 oct. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 3Q EPS $11.54 >REGN

31 oct. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 3Q Net $1.34B >REGN

25 oct. 2024, 20:25 UTC

Câștiguri

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 aug. 2024, 11:50 UTC

Câștiguri

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 aug. 2024, 10:37 UTC

Câștiguri

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q EPS $12.41 >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Net $1.43B >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Rev $3.55B >REGN

Comparație

Modificare preț

Regeneron Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

47.02% sus

Prognoză pe 12 luni

Medie 881.75 USD  47.02%

Maxim 1,120 USD

Minim 547 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRegeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

21 ratings

17

Cumpărare

3

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

554.18 / 603.77Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.